The U.S. pharmacy industry has entered a shakeout process that will ultimately reduce the number of U.S. pharmacy locations.
PHILADELPHIA (PRWEB) March 10, 2020
Today Drug Channels Institute, a leading provider of specialized management education for and about the pharmaceutical industry, released its exclusive, in-depth analysis of U.S. pharmacies and pharmacy benefit managers (PBMs). The new 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers provides the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system.
“Total prescription dispensing revenues of retail, mail, long-term care, and specialty pharmacies reached a record $446 billion in 2019,” says Drug Channels Institute CEO Adam J. Fein, Ph.D., the study's author and a widely regarded expert on pharmaceutical economics and the drug distribution system. “The largest insurers, PBMs, and specialty pharmacies have combined into vertically integrated organizations. They are poised to restructure U.S. drug channels by exerting greater control over patient access, sites of care, dispensing locations, and pricing.”
These findings are among the many insights and trends in this highly regarded report, now in its 11th edition. With 203 proprietary charts, exhibits, and data tables, it offers the most current economic information about specialty drugs, market structure, reimbursement, pharmacy and PBM profits, manufacturer rebates, patients’ out-of-pocket expenses, industry trends, and more.
“The U.S. pharmacy industry has entered a shakeout process that will ultimately reduce the number of U.S. pharmacy locations,” Fein adds. “At the same time, Amazon and well-funded technology-based startups are trying to disrupt the pharmacy industry.”
The report analyzes the crucial healthcare trends that will affect PBMs and pharmacies, including such topics as benefit designs, drug pricing, rebates, public policy, narrow networks, the 340B Drug Pricing Program, and many others. This year’s edition offers significant new information on such topics as PBMs’ profit in Managed Medicaid programs, direct and indirect remuneration (DIR) fees paid by pharmacies, and pharmacies’ profits from the 340B program.
About Drug Channels Institute